NEW YORK (GenomeWeb News) – Affymetrix today said that that it has penned a five-year gene-expression collaboration with the Peter MacCallum Cancer Centre in Australia.
 
Terms of the agreement call for Peter Mac researchers to use Affymetrix GeneChip technology for translational research projects. The first studies will cover ovarian cancer and carcinoma of unknown primaries.
 
Millennium Science will supply Peter Mac with Affy’s technology and provide technical support.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.